Download This PaperPharmaceutical Research and Development: What Do We Get for All that Money?
BMJ, 2012, DOI: 10.1136/bmj.e4348
5 Pages Posted: 10 May 2013 Last revised: 19 Jun 2013
Date Written: August 7, 2012
Abstract
Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones.
Keywords: pharmaceuticals, pharmaceutical policy, regulation, innovation crisis
Suggested Citation: Suggested Citation
Light, Donald W. and Lexchin, Joel, Pharmaceutical Research and Development: What Do We Get for All that Money? (August 7, 2012). BMJ, 2012, DOI: 10.1136/bmj.e4348, Available at SSRN: https://ssrn.com/abstract=2262843 or http://dx.doi.org/10.2139/ssrn.2262843
Do you have negative results from your research you’d like to share?
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.